Harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis of stage I–III breast cancer: Multicenter study
Metrics: PDF 292 views | Full Text 679 views | ?
Kazuhiro Kitajima1, Yasuo Miyoshi2, Tetsuro Sekine3, Hiroyuki Takei4, Kimiteru Ito5, Akihiko Suto6, Hayato Kaida7, Kazunari Ishii7, Hiromitsu Daisaki8 and Koichiro Yamakado1
1 Department of Radiology, Hyogo College of Medicine, Hyogo, Japan
2 Department of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo, Japan
3 Department of Radiology, Nippon Medical School Hospital, Tokyo, Japan
4 Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
5 Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan
6 Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
7 Department of Radiology, Kinki University Faculty of Medicine, Osaka, Japan
8 Department of Radiological Technology, School of Radiological Technology, Gunma Prefectural College of Health Sciences, Maebashi, Japan
Keywords: breast cancer; survival; fluorodeoxyglucose (FDG); positron emission tomography-computed tomography (PET-CT); harmonization
Received: October 29, 2020 Accepted: December 11, 2020 Published: January 19, 2021
Objectives: This study investigated harmonized pretreatment volume-based quantitative FDG-PET/CT parameters in breast cancer patients for prognostic value.
Results: During a median overall follow-up period of 5.3 years, 91 patients had recurrence and 40 died. Multivariate analysis of ER-positive/HER2-negative patients showed high maximum standardized uptake value (SUVmax) (p = 0.018), high total lesion glycolysis (TLG) (p = 0.010), and clinical N-classification (p = 0.0027) as independent negative predictors of RFS, while high maximum SUVmax (p = 0.037), advanced clinical T-classification (p = 0.030), and advanced TNM stage (p = 0.0067) were independent negative predictors of OS. For recurrence and death in HER2-positive patients, high total TLG (p = 0.037, p = 0.0048, respectively) and advanced TNM stage (p = 0.048, p = 0.046, respectively) were independent prediction factors. In the triple-negative group, independent factors related to recurrence and death were high maximum SUVmax (p = 0.0014, p = 0.0003, respectively) and advanced TNM stage (p < 0.0001, p < 0.0001, respectively).
Materials and Methods: Records of 546 stage I–III invasive breast cancer patients, including 344 estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 110 HER2-positive, and 92 triple-negative cases, treated at four institutions were reviewed retrospectively. Harmonized primary tumor and nodal maximum SUVmax, metabolic tumor volume (MTV), and TLG indicated in pretreatment FDG-PET/CT results were analyzed. Evaluations of relationships of clinicopathological factors, volume-based quantitative parameters, recurrence-free survival (RFS), and overall survival (OS) for each subtype were performed with a Cox proportional hazards model and log-rank test.
Conclusions: The results indicated that potential surrogate markers for prognosis in patients with the three main subtypes of operable breast cancer include harmonized pretreatment quantitative volume-based FDG-PET/CT parameters, particularly whole-lesion SUVmax and TLG.
Breast cancer is a heterogeneous group of diseases that show various types of histological differentiation and clinical courses, as well as responses to treatment. Management of affected patients is generally decided following examinations of obtained specimens to determine tumor-node-metastasis (TNM) stage, histologic tumor grade, and levels of hormone receptors and molecular markers . Among prognosis-related immunohistochemical factors, including hormone receptors such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67, ER-positive/HER2-negative, HER2-positive, and triple-negative, are three primary entities typically considered clinically based on immunohistochemical findings of the primary tumor biopsy specimen. Recently, noninvasive diagnostic tools have been gaining popularity for prediction of tumor behavior, with magnetic resonance spectroscopy (MRS) and diffusion-weighted imaging (DWI) with magnetic resonance imaging (MRI) reported to provide surrogate imaging biomarkers showing correlations with clinicopathological prognostic factors [2, 3]. In addition, standardized uptake value (SUV), metabolic tumor volume (MTV), and tumor lesion glycolysis (TLG) derived from 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) findings are reported to have correlations with clinicopathological prognostic factors and considered to be prognosis prediction factors [2–6].
Biological and technical factors related to the PET scanner model used, as well as the acquisition protocol and reconstruction algorithm, along with various parameters can result in varied SUV findings. Thus, a harmonization strategy is necessary for comparing semi-quantitative PET parameters among available imaging methods, which is a notably relevant issue for multicenter trials employing different PET systems. Established harmonization programs include the EANM/EARL program [7, 8] and Quantitative Imaging Biomarker Alliance (QIBA/UPICT) [9, 10], which provide comparisons of SUV metrics across different systems. Those are especially useful for multicenter studies, though can also be used by single institutions that may have several different PET systems. To the best of our knowledge, no previous study has evaluated harmonization of FDG-PET/CT quantitative parameters in breast cancer cases as potential surrogate markers. This investigation examined harmonized quantitative volume-based FDG-PET/CT parameters for predicting prognosis in patients with breast cancer.
With the GXL and Biograph Duo (no filter needed for either system), SUVmax fell within the JSNM reference range. The value for full-width at half maximum (FWHM) for the additional gaussian filter resulting in SUVmax within the JSNM reference was 3.4 mm for the Discovery 600, and 5.9 and 5.8 mm for the Gemini TF1 and TF2 systems, respectively (Figure 1).
Figure 1: Recovery coefficient for five different PET scanners obtained from 30-minute PET imaging. (A) Pre-harmonization compared to (B) post-harmonization recovery coefficient.
Table 1 shows patient and tumor characteristics. After excluding invasive ductal carcinoma, histology results for the ER-positive/HER2-negative type patients were myxoid carcinoma (n = 14), invasive lobular carcinoma (n = 5), and apocrine carcinoma (n = 1), while those in the HER2-positive type were myxoid carcinoma (n = 3), invasive lobular carcinoma (n = 2), and apocrine carcinoma (n = 2), and in triple-negative type invasive lobular carcinoma (n = 1) and apocrine carcinoma (n = 3).
Table 1: Patient and tumor characteristics
|Number of patients||344||110||92|
|Age (years, mean ± SD)||58.7 ± 13.5||57.2 ± 13.6||56.5 ± 15.0|
|IDC||324 (94.2%)||103 (93.6%)||88 (95.7%)|
|Others||20 (5.8%)||7 (6.4%)||4 (4.3%)|
|Primary longest size (mm, mean ± SD)||24.7 ± 13.9||33.6 ± 18.2||28.3 ± 13.7|
|Estrogen receptor||324 (100%)||62 (56.4%)||0 (0%)|
|Progesterone receptor||285 (82.8%)||43 (39.1%)||0 (0%)|
|HER-2/neu||0 (0%)||110 (100%)||0 (0%)|
|Ki-67 index status|
|< 20%||206 (59.9%)||22 (20.0%)||20 (21.7%)|
|≥ 20%||138 (40.1%)||88 (80.0%)||72 (78.3%)|
|Grade1||241 (70.1%)||32 (29.1%)||24 (26.1%)|
|Grade2||64 (18.6%)||24 (21.8%)||28 (30.4%)|
|Grade3||39 (11.3%)||54 (49.1%)||40 (43.5%)|
|Clinical T status|
|T1||164 (47.7%)||21 (19.1%)||28 (30.4%)|
|T2||153 (44.5%)||64 (58.2%)||55 (59.8%)|
|T3||15 (4.4%)||12 (10.9%)||2 (2.2%)|
|T4||12 (3.5%)||13 (11.8%)||7 (7.6%)|
|Pathological N status|
|N0||212 (61.6%)||44 (40.0%)||44 (47.8%)|
|N1||110 (32.0%)||42 (38.2%)||38 (41.3%)|
|N2||12 (3.5%)||11 (10.0%)||5 (5.4%)|
|N3||10 (2.9%)||13 (11.8%)||5 (5.4%)|
|I||128 (37.2%)||15 (13.6%)||18 (19.6%)|
|II||173 (50.3%)||58 (52.7%)||57 (62.0%)|
|III||43 (12.5%)||37 (33.6%)||17 (18.5%)|
|No||166 (48.3%)||41 (37.3%)||30 (32.6%)|
|Yes||178 (51.7%)||69 (62.7%)||62 (67.4%)|
ER-positive/HER2-negative type (n = 344)
There were 132 patients with pathological regional nodal metastasis, of whom 83 (62.9%) had abnormal FDG uptake in a regional node detected by FDG-PET/CT. Among those, primary tumor SUVmax was greater than nodal SUVmax in 64 (77.1%) and lower than nodal SUVmax in 19 (22.9%).
For the ER+/HER2 cancer patients, median overall follow-up duration was 70.5 months (13.9–125.6 months), during which 13 (3.8%) died. Patients who died from cancer had a significantly higher maximum SUVmax as compared to those who survived (11.33 ± 5.43 vs. 4.33 ± 3.02, p < 0.0001). ROC curve analysis and log-rank testing results showed a significantly lower OS rate for patients with high maximum SUVmax (≥ 4.54) as compared to a lower value (p < 0.0001) (Figure 2A). Furthermore, patients with death from cancer had a significantly higher total MTV that those who survived (53.13 ± 56.97 vs. 5.85 ± 7.53, p < 0.0001) and those with a high total MTV (≥ 5.04) had a significantly lower OS rate that those with a low total MTV (p < 0.0001) (Figure 2B). In addition, significantly higher TLG was seen in patients who had a cancer-related death than in survivors (401.37 ± 594.14 vs. 18.08 ± 33.57, p < 0.0001), while a significantly lower OS rate was noted in those with high total TLG (≥ 13.80) than in patients with low total TLG (p < 0.0001) (Figure 2C).
Figure 2: Overall survival (OS) of ER-positive/HER2-negative breast cancer patients (n = 344) (Kaplan-Meier survival analysis). A significantly lower OS rate was found in patients (A) with a high maximum SUVmax value (≥ 4.54) as compared to those with lower values (p < 0.0001), (B) with high total MTV (≥ 5.04) as compared to those with lower values (p < 0.0001), (C) with high total TLG (≥ 13.8) as compared to those with lower values (p < 0.0001), and (D) classified as stage II or III as compared to those classified as stage I (p = 0.027).
High maximum SUVmax (p < 0.0001), high total MTV (p < 0.0001), high total TLG (p < 0.0001), presence of clinical regional node metastasis (p < 0.0001), advanced clinical T classification (p = 0.0013), presence of pathological regional node metastasis (p < 0.0001), advanced TNM stage (p = 0.027) (Figure 2D), high Ki-67 expression (p = 0.0040), and presence of NAC (p = 0.014) were shown by univariate analysis to have a significant association with death from cancer (Supplementary Table 1). On the other hand, no such association was seen with histology subtype (p = 0.58), high nuclear grade (p = 0.34), ER-negative (p = 0.93), or PR-negative (p = 0.66). High maximum SUVmax (p = 0.037), advanced clinical T classification (p = 0.030), and advanced TNM stage (p = 0.00067) were revealed to be independent factors for death prediction in multivariate analysis.
Thirty-six (10.5%) ER+/HER2- cancer patients had recurrence, with a median overall follow-up period of 67.6 months (range 13.1–125.6 months). High maximum SUVmax (p < 0.0001), high total MTV (p < 0.0001), high total TLG (p < 0.0001), presence of clinical regional node metastasis (p < 0.0001), advanced clinical T classification (p < 0.0001), presence of pathological regional node metastasis (p < 0.0001), advanced TNM stage (p < 0.0001), high Ki-67 expression (p = 0.0098), and presence of NAC (p = 0.0043) were each shown by univariate analysis results to have a significant association with recurrence (Supplementary Table 1), whereas histology subtype (p = 0.65), high nuclear grade (p = 0.24), ER-negative (p = 0.79), and PR-negative (p = 0.18) were not significantly associated. High maximum SUVmax (p = 0.018), high total TLG (p = 0.010), and presence of regional node metastasis shown by PET (p = 0.0027) were independent factors for predicting recurrence in multivariate analysis results.
HER2-positive type (n = 110)
Pathological regional nodal metastasis was noted in 66 patients and FDG-PET/CT results showed abnormal FDG uptake in a regional node in 49 (74.2%) of those cases, among which primary tumor SUVmax was higher than nodal SUVmax in 44 (89.8%).
HER2-positive cancer patients had a median overall follow-up period of 64.8 months (11.3–123.9 months), during which 18 (16.4%) died. A significantly higher maximum SUVmax was shown for those who died of cancer as compared to surviving patients (11.33 ± 5.43 vs. 4.33 ± 3.02, p < 0.0001). Also, a significantly lower OS rate was seen in patients with a high maximum SUVmax (≥ 6.44) as compared to a low maximum SUVmax (p = 0.0004) (Figure 3A). Additionally, patients with cancer death had a significantly higher total MTV than those who survived (49.99 ± 37.32 vs. 13.15 ± 23.13, p < 0.0001), while patients with high total MTV (≥ 6.60) had a significantly lower OS rate that those with low total MTV (p = 0.0002) (Figure 3B). In cancer death cases, significantly higher TLG as compared to survival cases was found (285.43 ± 255.62 vs. 66.68 ± 166.76, p < 0.0001) and patients with high total TLG (≥ 20.0) had a significantly lower OS rate than those with low total TLG (p < 0.0001) (Figure 3C).
Figure 3: Overall survival (OS) of HER2-positive breast cancer patients (n = 110) (Kaplan-Meier survival analysis). A significantly lower OS rate was found in patients (A) with high maximum SUVmax (≥ 6.44) as compared to those with lower values (p = 0.0004), (B) with high total MTV (≥ 6.60) as compared to those with lower values (p = 0.0002), (C) with high total TLG (≥ 20.0) as compared to those with lower values (p < 0.0001), and (D) classified as stage III as compared to those classified as stage I or II (p < 0.0001).
Univariate analysis results demonstrated that high maximum SUVmax (p = 0.0004), high total MTV (p = 0.0002), high total TLG (p < 0.0001), presence of clinical regional node metastasis (p = 0.0003), advanced clinical T classification (p < 0.0001), presence of pathological regional node metastasis (p = 0.0008), advanced TNM stage (p < 0.0001) (Figure 3D), high nuclear grade (p = 0.011), and high Ki-67 expression (p = 0.049) were significantly associated with death (Supplementary Table 2). High total TLG (p = 0.0048) and advanced TNM stage (p = 0.046) were independent factors for predicting death in multivariate analysis.
A median overall follow-up period of 59.6 months (8.3–123.9 months) was found in the HER2-positive cancer patients, of whom 35 (31.8%) demonstrated recurrence. Univariate analysis results showed that high maximum SUVmax (p < 0.0001), high total MTV (p < 0.0001), high total TLG (p < 0.0001), presence of clinical regional node metastasis (p < 0.0001), advanced clinical T classification (p < 0.0001), presence of pathological regional node metastasis (p < 0.0001), advanced TNM stage (p < 0.0001), high nuclear grade (p = 0.0014), and high Ki-67 expression (p = 0.0027) had a significant association with recurrence (Supplementary Table 2). In results of multivariate analysis, high total TLG (p = 0.037) and advanced TNM stage (p = 0.024) were found to be independent factors for recurrence prediction.
Triple-negative (n = 92)
Among the 48 patients with pathological regional nodal metastasis, abnormal FDG uptake in a regional node was detected in 42 (87.5%) by FDG-PET/CT. Of those 42, primary tumor SUVmax was higher than nodal SUVmax in 29 (69.0%).
For triple negative cancer patients, median overall follow-up was 64.8 months (15.0–117.9 months), during which 9 (9.8%) died. Those who died of cancer had a significantly higher maximum SUVmax as compared to patients who survived (10.91 ± 4.14 vs. 6.75 ± 4.25, p = 0.0064), while those with a high maximum SUVmax (≥ 7.0) had a significantly lower OS rate as compared to patients with a low maximum SUVmax (p = 0.0054) (Figure 4A). Additionally, a significantly higher total MTV was noted in cancer death than survival cases (35.28 ± 44.22 vs. 8.31 ± 9.14, p < 0.0001) and patients with high total MTV (≥ 6.70) showed a significantly lower OS rate as compared to those with low total MTV (p = 0.0005) (Figure 4B). Cancer death cases also showed significantly higher TLG as compared to survival cases (258.7 ± 448.2 vs. 40.03 ± 53.8, p < 0.0001) and patients with high total TLG (≥ 22.5) had a significantly lower OS rate as compared to those with low total TLG (p = 0.0077) (Figure 4C).
Figure 4: Overall survival (OS) of triple-negative breast cancer patients (n = 92) (Kaplan-Meier survival analysis). A significantly lower OS rate was found in patients (A) with high maximum SUVmax (≥ 7.0) as compared to those with lower values (p = 0.0054), (B) with high total MTV (≥ 6.7) as compared to those with lower values (p = 0.0005), (C) with high total TLG (≥ 22.5) as compared to those with lower values (p = 0.0077), and (D) classified as stage III as compared to those classified as stage I or II (p < 0.0001).
Univariate analysis revealed that high maximum SUVmax (p = 0.0054), high total MTV (p = 0.0005), high total TLG (p = 0.0077), presence of clinical regional node metastasis (p = 0.0001), advanced clinical T classification (p = 0.0017), presence of pathological regional node metastasis (p = 0.0072), and advanced TNM stage (p < 0.0001) (Figure 4D) had a significant association with death (Supplementary Table 3). In multivariate analysis, results showed high maximum SUVmax (p = 0.0003) and advanced TNM stage (p < 0.0001) as independent factors for predicting death.
For triple negative cancer patients, the median overall follow-up period was 59.4 months (12.5–117.9 months), during which time 20 (21.7%) had recurrence. Univariate analysis results revealed that high maximum SUVmax (p = 0.0021), high total MTV (p = 0.0003), high total TLG (p = 0.0036), presence of clinical regional node metastasis (p = 0.014), advanced clinical T classification (p = 0.0021), presence of pathological regional node metastasis (p = 0.016), advanced TNM stage (p < 0.0001), and presence of NAC (p = 0.0047) were significantly associated with recurrence (Supplementary Table 3), while high maximum SUVmax (p = 0.0014), advanced TNM stage (p < 0.0001), and presence of NAC (p = 0.0037) were shown in multivariate analysis results to be independent factors for recurrence prediction.
This is the first known investigation of breast cancer patients (stage I–III) that used harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis prediction. Primary tumor and nodal SUVmax, as well as TLG values were found to be prominent potential surrogate markers for prognosis in patients with the three major subtypes, indicating their importance for providing better individualized care.
Establishment of different PET/CT scanner types at the same institution is becoming common, which affects both clinical practice and multicenter trials. Thus, methods for harmonization of PET quantitative values are needed. There have been several evaluations of the utility of SUVmax harmonization for evaluating response to chemotherapy in various types of cancer patients, including lung, cervical, and rectal, as well as colorectal liver metastasis, malignant lymphoma, and malignant melanoma. Those findings have demonstrated a significant association of harmonized metabolic PET response classification with final clinical response assessment and its better ability for predicting disease-free survival as compared to a non-harmonized PET classification [11–14]. Another recent study also presented findings showing harmonized SUVmax to be an independent prognostic factor of progression-free survival in non-small-cell lung cancer patients . PET used for texture analysis or radiomic studies is sensitive to acquisition and reconstruction parameters, which can hinder pooling of data acquired with different scanners or protocols. Efficient harmonization methods for multicenter radiomic studies of patients with breast and lung cancer that use FDG-PET/CT have been proposed by two different groups [16, 17].
As for tumor subtype in the present cohort, the mean maximum SUVmax values for HER2-positive and triple-negative tumors were 7.92 ± 4.59 and 7.16 ± 4.40, respectively, both higher than that for ER-positive/HER2-negative tumors (4.59 ± 3.40) (p < 0.001 and p < 0.001, respectively), findings similar to previous reports [4, 6, 18]. Other studies of breast cancer have found that primary tumor quantitative FDG-PET/CT parameters are correlated with known prognostic pathological parameters, while those were also shown useful for prognosis prediction without the need for division according to molecular subtype [2, 4–6]. More recently, reports regarding the usefulness of volume-based quantitative parameters (SUVmax, MTV, TLG) for predicting prognosis using major receptor types have been presented. A study of ER+/HER2- cancer patients showed primary tumor MTV as an independent factor for predicting recurrence , while primary tumor SUVmax was demonstrated to be an independent factor in another report . Also, primary tumor SUVmax was shown to be an independent factor with influence on recurrence in triple-negative cancer patients . The present results are similar to those, though this is the first known evaluation HER2-positive cancer cases to be presented.
Although previous studies of stage operable breast cancer patients only evaluated primary tumor quantitative FDG-PET/CT values as imaging biomarkers [2, 4–6, 18–21], cases with a lower primary tumor SUVmax value as compared to that for nodal SUVmax are commonly encountered in clinical situations. In the present cohort as well, it was observed in 10.2–30.9% and we defined that as maximum SUVmax, which is considered to be a strong point of this report.
The present study has limitations including its retrospective design, as that may limit generalization of the conclusions and could lead to statistical errors. Furthermore, in the enrolled patients, heterogeneous chemotherapy and hormonal therapy regimens were used.
Materials and Methods
This retrospective study of FDG-PET/CT findings was conducted by Hyogo College of Medicine Hospital, Kindai University Hospital, Nippon Medical School Hospital, and National Cancer Center Hospital. An appropriate review board at each gave approval to the protocol and waived the need for patient-informed consent. A total of 606 records of females newly diagnosed with stage I-III invasive breast cancer and who underwent pretreatment FDG-PET/CT examinations between January 2010 and December 2016 were examined. Exclusion criteria were bilateral breast cancer (n = 15), no focal uptake shown by FDG-PET/CT (n = 24), invasive tumor size < 1 cm (n = 13), and no immunohistochemical data available (n = 8), thus 546 patients were finally enrolled. A mastectomy was performed in 315 and 231 underwent breast-conserving surgery. Tumor subtype was ER-positive/HER2-negative in 344, HER2-positive in 110, and triple-negative in 92 of the patients. To determine T status, magnetic resonance imaging (MRI) and ultrasound, and also clinical examination results were employed. Axillary node diagnostic tool determination was based on aspiration cytology, sentinel node biopsy, and axillary node dissection assessments, while for histopathologic characteristics, core needle biopsy and surgical resection findings were used.
Of the total cohort, 178 ER-positive/HER2-negative breast cancer, 69 HER2-positive cancer, and 62 triple-negative patients underwent neoadjuvant chemotherapy (NAC) and/or hormonal therapy prior to surgery. For NAC, an anthracycline-containing regimen, anthracycline followed by taxane, or taxane-based regimen was administered. Hormonal therapy was administered to patients with hormone receptor-positive cancer and a trastuzumab-based regimen to those with HER2-positive.
Adjuvant chemotherapy or hormonal therapy was administered, and radiotherapy was also performed after surgery in all cases. Mammography, ultrasound, CT, bone scanning, and FDG-PET/CT were used for determining disease recurrence, metastasis, and progression during follow-up. Any suggestive lesion was histologically confirmed by fine-needle aspiration cytology or clinical follow-up findings, including therapeutic response.
The participating institutions employed different PET/CT scanner systems, including Gemini GXL (Philips Medical Systems, Eindhoven, The Netherlands), Gemini TF (Philips Medical Systems), Biograph Duo (Siemens Healthcare, Erlangen, Germany), and Discovery 600 (GE Healthcare, WI, USA), and their clinical parameters are presented in Table 2. Prior to the examination, patients fasted for five hours and blood glucose was measured immediately prior to injection of FDG at 3.0–4.0 MBq/kg of body weight. None had a blood glucose level greater than 200 mg/dL. Approximately 60 minutes after the injection, static emission images were obtained, during which the patients were allowed to breathe normally.
Table 2: Clinical parameters of PET scanners
|Scanner||Gemini GXL||Gemini TF1||Gemini TF2||Biograph Duo||Discovery 600|
|FDG injection dose (MBq/kg)||4||3||4||3||4|
|Scan time (sec) for each bed||90||90||80||110||120|
|Reconstruction||line-of-response row-action maximum likelihood algorithm (LOR-RAMLA)||3D-OSEM||Full-list mode TOF 3D-OSEM||3D-OSEM||3D-OSEM|
|FWHM of filter (mm)||5||5|
|Matrix||144 × 144||144 × 144||144 × 144||128 × 128||192 × 192|
|Pixel size (mm)||4 × 4 × 4||4 × 4 × 4||4 × 4 × 4||5.31 × 5.31 × 5||2.6 × 2.6 × 2.6|
An experienced reader (12 years of experience with oncologic FDG-PET/CT) who had no knowledge of other imaging results or clinical and histopathologic data retrospectively reviewed all of the FDG-PET/CT images. RAVAT (Nihon Medi-Physics Co. Ltd., Tokyo, Japan), a commercially available software package able to harmonize SUVs obtained with different PET/CT systems in a range advocated by the Japanese Society of Nuclear Medicine (JSNM) using phantom data, was employed . SUVmax was defined as maximum SUV within the target volume and determined using the following formula: concentration of radioactivity in volume of interest (VOI) (MBq/ml) × total body weight (kg)/injected radioactivity (g/MBq). As for SUVmean, that was calculated as summed SUV in each voxel in the target volume divided by the number of voxels within the target volume. MTV was measured automatically inside the tumor VOI, with the margin threshold set at 40% of SUVmax. Then, TLG was t as SUVmean × MTV, taking into consideration both metabolic activity and tumor burden. “Maximum SUVmax” was defined as the maximum for all lesions (primary tumor and regional nodal metastases), while “total MTV” and “total TLG” were calculated by summing the corresponding values for each lesion in individual patients.
ER, PR, HER2, and Ki67 expression levels were examined in tissue samples that had undergone immunohistochemical staining, as well as formalin fixation and paraffin embedding, with quantitative levels determined. In addition, the percentage of nuclear staining in cancer cells for ER, PR, and Ki67 was determined, with the cutoff value for ER and PR set at 1%, and that for Ki67 at 20%. Tumors that had an immunohistochemical score of 3 or showed in situ hybridization-positive fluorescence with an immunohistochemical score of 2 were defined as HER2-positive.
Student’s t test was used for comparisons of patients with or without recurrence or death, and to determine the optimal threshold receiver operating characteristics (ROC) analysis was performed. Recurrence-free survival (RFS), defined as time elapsed from date of diagnosis to recurrence, and overall survival (OS), time until death or date of the last follow-up visit when neither progression nor death occurred during follow-up were evaluated in this long-term follow-up study. The Kaplan-Meier method and log-rank test results were employed to determine survival curves.
Cox proportional hazards logistic regression was used to evaluate the prognostic value of individual variables. To quantify risk of recurrence and death for primary clinical T classification, ER, PR, HER2, Ki-67, nuclear grade, regional node metastasis shown by PET (clinical N classification), pathological regional node metastasis (pathological N classification), TNM stage, histology subtype, maximum SUVmax, total MTV, and total TLG, univariate Cox proportional hazards modeling was used. Then, significant or borderline univariate variables (p < 0.1) were subjected to multivariate analysis, except for parameters with insufficient data. Cox model results are expressed as hazard ratio with 95% confidence interval (CI). The SAS software package, version 9.3 (SAS Institute Inc., Cary, NC, USA), was used for statistical analysis, with p < 0.05 considered to indicate significance.
This retrospective study was approved by appropriate institutional review boards and the need for patient informed consent was waived.
We concluded that harmonized quantitative volume-based values, especially those for the primary tumor and nodal SUVmax and TLG, obtained with FDG-PET/CT can provide useful information regarding prognosis for both recurrence and death in patients with operable invasive breast cancer, including all three main subtypes. The findings presented here are considered useful for improving care of individual patients.
ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; RFS: recurrence-free survival; OS: overall survival; TNM: tumor-node-metastasis; PR: progesterone receptor; FDG: 18F-fulorodeoxyglucose; PET/CT: positron emission tomography/computed tomography; MRI: magnetic resonance imaging; NAC: neoadjuvant chemotherapy; LOR-RAMLA: line-of-response row-action maximum likelihood algorithm; OSEM: ordered-subset expectation maximization; TOF: time of flight; JSNM: Japanese Society of Nuclear Medicine; VOI: volume of interest; ROC: receiver operating characteristics; CI: confidence interval.
CONFLICTS OF INTEREST
Authors have no conflicts of interest to declare.
This work was supported by a JSPS KAKENHI grant (number 19K08187).
1. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016; 66:43–73. https://doi.org/10.3322/caac.21319. [PubMed].
2. Baba S, Isoda T, Maruoka Y, Kitamura Y, Sasaki M, Yoshida T, Honda H. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging. J Nucl Med. 2014; 55:736–742. https://doi.org/10.2967/jnumed.113.129395. [PubMed].
3. Cho N, Im SA, Kang KW, Park IA, Song IC, Lee KH, Kim TY, Lee H, Chun IK, Yoon HJ, Moon WK. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel 1H-magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. Eur Radiol. 2016; 26:2279–2290. https://doi.org/10.1007/s00330-015-4014-7. [PubMed].
4. Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, Katsuura T, Maruyama K, Hirota S. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015; 42:1371–1377. https://doi.org/10.1007/s00259-015-3070-1. [PubMed].
5. Jo JE, Kim JY, Lee SH, Kim S, Kang T. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer. Acta Radiol. 2015; 56:1463–1470. https://doi.org/10.1177/0284185114556929. [PubMed].
6. Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, Espié M, de Roquancourt A, Hindié E, Hatt M, Visvikis D. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III Breast Cancer? Eur J Nucl Med Mol Imaging. 2015; 42:1682–1691. https://doi.org/10.1007/s00259-015-3110-x. [PubMed].
7. Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017; 44:17–31. https://doi.org/10.1007/s00259-017-3740-2. [PubMed].
8. Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y, Boellaard R. EANM/EARL FDG-PET/CT accreditation-summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging. 2018; 45:412–422. https://doi.org/10.1007/s00259-017-3853-7. [PubMed].
9. Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, Perlman ES, Kinahan PE, Christian PE, Hoekstra OS, Dorfman GS. Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials. J Nucl Med. 2015; 56:955–961. https://doi.org/10.2967/jnumed.115.158402. [PubMed].
10. Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013; 40:1507–1515. https://doi.org/10.1007/s00259-013-2465-0. [PubMed].
11. Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, Aide N. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013; 40:985–996. https://doi.org/10.1007/s00259-013-2391-1. [PubMed].
12. Quak E, Le Roux PY, Lasnon C, Robin P, Hofman MS, Bourhis D, Callahan J, Binns DS, Desmonts C, Salaun PY, Hicks RJ, Aide N. Does PET SUV harmonization affect PERCIST response classification? J Nucl Med. 2016; 57:1699–1706. https://doi.org/10.2967/jnumed.115.171983. [PubMed].
13. Mattoli MV, Calcagni ML, Taralli S, Indovina L, Spottiswoode BS, Giordano A. How often do we fail to classify the treatment response with [18F]FDG PET/CT acquired on different scanners? Data from clinical oncological practice using an automatic tool for SUV harmonization. Mol Imaging Biol. 2019; 21:1210–1219. https://doi.org/10.1007/s11307-019-01342-5. [PubMed].
14. Weisman AJ, Bradshaw TJ, Namías M, Jeraj R. Impact of scanner harmonization on PET-based treatment response assessment in metastatic melanoma. Phys Med Biol. 2020 Sep 9. https://doi.org/10.1088/1361-6560/abb6bb. [Epub ahead of print]. [PubMed]
15. Houdu B, Lasnon C, Licaj I, Thomas G, Do P, Guizard AV, Desmonts C, Aide N. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. Eur J Nucl Med Mol Imaging. 2019; 46:421–428. https://doi.org/10.1007/s00259-018-4151-8. [PubMed].
16. Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, Soussan M, Frouin F, Frouin V, Buvat I. A postreconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med. 2018; 59:1321–1328. https://doi.org/10.2967/jnumed.117.199935. [PubMed].
17. Dissaux G, Visvikis D, Da-Ano R, Pradier O, Chajon E, Barillot I, Duvergé L, Masson I, Abgral R, Santiago Ribeiro MJ, Devillers A, Pallardy A, Fleury V, et al. Pretreatment 18F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: A multicentric study. J Nucl Med. 2020; 61:814–820. https://doi.org/10.2967/jnumed.119.228106. [PubMed].
18. Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumor 18F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015; 25:1172–1181. https://doi.org/10.1007/s00330-014-3452-y. [PubMed].
19. Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, Merlet P, Lemarignier C. 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res. 2017; 19:3. https://doi.org/10.1186/s13058-016-0793-2. [PubMed].
20. Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, Ryu HS, Kim WH, Chang JM, Cho N, Moon WK, Cheon GJ. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. Eur J Nucl Med Mol Imaging. 2016; 43:1574–1584. https://doi.org/10.1007/s00259-016-3418-1. [PubMed].
21. Yue Y, Cui X, Bose S, Audeh W, Zhang X, Fraass B. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. Breast Cancer Res Treat. 2015; 153:607–616. https://doi.org/10.1007/s10549-015-3558-1. [PubMed].
22. Tsutsui Y, Daisaki H, Akamatsu G, Umeda T, Ogawa M, Kajiwara H, Kawase S, Sakurai M, Nishida H, Magota K, Mori K, Sasaki M; J-Hart study group. Multicentre analysis of PET SUV using vendor-neutral software: the Japanese harmonization technology (J-Hart) study. EJNMMI Res. 2018; 8:83. https://doi.org/10.1186/s13550-018-0438-9. [PubMed].
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.